Posted in Mobile Health by Chris Newmarker on January 30, 2015 Why would two women who visit the doctor with identical early symptoms of multiple sclerosis have vastly different outcomes 10 years later? That’s what pharmaceutical ...
Biogen Idec today announced that FAMPYRA(prolonged-release fampridine tablets) has been made available in Ireland for the symptomatic treatment of walking impairment in adults with Multiple Sclerosis (MS). FAMPYRA is a prescription drug and ...
Tags: FAMPYRA, HSE, Biogen Idec, Named Patient Supply
Sunesis Pharmaceuticals has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec, is for global commercial rights to SNS-062, a ...
Tags: Sunesis Pharmaceuticals, Medicine
Biogen Idec (NASDAQ: BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that ...
Rainbow Coral and its joint venture partner, Therakine, have reached a major new milestone in the development of a revolutionary new drug delivery technology. The companies reached terms to initiate Phase II of research and analysis on a ...
Tags: RBCC, Drug Delivery Development
Proteostasis Therapeutics and Biogen Idec have collaborated to research and develop new therapies based on the inhibition of Usp14, a deubiquitinating enzyme, for the treatment of certain neurodegenerative disorders. Under the deal, ...
Biogen Idec announced that the US Food and Drug Administration (FDA) has extended its review of a marketing application for the long-lasting recombinant factor IX Fc fusion protein Alprolix for haemophilia B by three months. The company ...
A multiple-sclerosis drug that was at the center of Sanofi SA's SAN.FR +1.12% $20 billion takeover battle for Genzyme Corp. three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide. The ...
Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets. Under the terms ...
Tags: Adimab, Drug Discovery
Biogen has announced acceptance of marketing applications of Plegridy(peginterferon beta-1a) for review by the US and EU regulatory authorities. Plegridy, a member of the interferon class of treatments, is a pegylated subcutaneous ...
Tags: Biogen, Marketing Applications
Biogen Idec is seeking FDA approval for Plegridy (Peginterferon Beta-1a) as multiple sclerosis (MS) medication. The company submitted a biologics license application (BLA) to the FDA for its pegylated subcutaneous injectable candidate ...
Tags: Biogen IDEC, FDA Approval
The US Food and Drug Administration (FDA) has approved Biogen Idec's Tecfidera (dimethyl fumarate), a new first-line oral capsule for people suffering from relapsing forms of multiple sclerosis (MS). Tecfidera reduces relapses and ...
Tags: FDA, Biogen capsule, multiple sclerosis
Biogen Idec is seeking marketing approval from the US Food and Drug Administration (FDA) for recombinant factor VIII Fc fusion protein (rFVIIIFc) therapy to treat hemophilia A. The company has submitted a biologics license application ...
Tags: Biogen Idec, FDA, hemophilia A
The US Food and Drug Administration (FDA) has accepted Biogen Idec's biologics license application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. Using the company's ...
Tags: FDA, Idec BLA, hemophilia B
Biogen Idec and Elan are seeking approvals from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for first-line use of Tysabri (natalizumab) in anti-JCV antibody negative patients with multiple sclerosis (MS). ...